We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading at $64.49 as of ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...

Novo Nordisk (NYSE:NVO) is focused on researching, developing, manufacturing, and distributing pharmaceutical products. For ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The India launch of Eli Lilly's Mounjaro in India has triggered a huge wave of enquiries from those looking for its ...

A surprise executive order could delay drug price cuts and supercharge profits for the industry's biggest players ...

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the new publication[2] of positive in vivo data, in the journal Diabetes, Metabolic Syndrome ...

Blockbuster weight loss meds like Ozempic and Wegovy are now linked to a rare eye disease that can lead to blindness.

President Donald Trump signed an executive order on the healthcare sector yesterday, aiming to lower prescription drug prices for Americans, ...

With broadcasts of the college football and NFL playoffs, as well as the men’s and women’s college basketball tournaments, many drugmakers looked to sports for advertising opportunities in Q1.